Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:NSCI NASDAQ:SBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNSCINanalysis ScientificC$0.21-6.8%C$0.23C$0.18▼C$0.45C$23.54M-0.87393483,925 shs43,125 shsSBTXSilverback Therapeutics$10.07-5.8%$16.05$2.80▼$8.97$211.66M0.6337,931 shs5.21 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNSCINanalysis Scientific0.00%+10.81%-12.77%-18.00%-52.87%SBTXSilverback Therapeutics-5.80%-13.34%-43.99%-30.50%-15.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNSCINanalysis ScientificC$0.21-6.8%C$0.23C$0.18▼C$0.45C$23.54M-0.87393483,925 shs43,125 shsSBTXSilverback Therapeutics$10.07-5.8%$16.05$2.80▼$8.97$211.66M0.6337,931 shs5.21 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNSCINanalysis Scientific0.00%+10.81%-12.77%-18.00%-52.87%SBTXSilverback Therapeutics-5.80%-13.34%-43.99%-30.50%-15.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNSCINanalysis Scientific 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNSCINanalysis ScientificC$44.93M0.52C$0.02 per share8.93C$0.21 per share0.98SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNSCINanalysis Scientific-C$12.93M-C$0.11N/A∞N/A-32.75%-38.02%-7.55%N/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNSCINanalysis ScientificN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNSCINanalysis Scientific71.721.421.11SBTXSilverback TherapeuticsN/A67.8767.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNSCINanalysis Scientific0.03%SBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipNSCINanalysis Scientific3.95%SBTXSilverback Therapeutics34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNSCINanalysis Scientific249114.82 millionN/ANot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableNSCI, SBTX, APTA, and HEMO HeadlinesRecent News About These CompaniesSilverback Therapeutics (NASDAQ:SBTX) Shares Up 0.4% - Time to Buy?August 20, 2025 | marketbeat.comMeet the Silverback, the Leader of the TroopOctober 17, 2024 | pbs.orgP10 Fun Facts About Mountain GorillasSeptember 18, 2024 | nationalgeographic.comNCapstanTx secures $165 million to deliver precise in vivo cell engineeringJuly 28, 2024 | pharmaphorum.comPARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comWild IslesMarch 12, 2023 | wwf.org.ukWA look back at RNA Therapeutics – day oneFebruary 23, 2023 | pharmaphorum.comPSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNovember 8, 2022 | finance.yahoo.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 28, 2022 | markets.businessinsider.comFDA accepts ARS Pharma’s NDA for NeffyOctober 24, 2022 | thepharmaletter.comTSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIOctober 23, 2022 | kentuckytoday.comKSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisOctober 21, 2022 | finance.yahoo.comIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?October 19, 2022 | aaii.comASHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNOctober 12, 2022 | bakersfield.comBINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 17, 2022 | markets.businessinsider.comSBTX Silverback Therapeutics, Inc.September 15, 2022 | seekingalpha.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTSeptember 6, 2022 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSCI, SBTX, APTA, and HEMO Company DescriptionsNanalysis Scientific CVE:NSCIC$0.20 -0.02 (-6.82%) As of 09/5/2025 03:59 PM EasternNanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.Silverback Therapeutics NASDAQ:SBTX$10.07 -0.62 (-5.80%) As of 09/5/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
